摘要
目的探究参芪扶正方结合化疗(培美曲塞+奥沙利铂)治疗晚期贲门癌临床效果。方法纳入晚期贲门癌患者102例(2019年5月—2021年10月收治),将其以随机数字表法分成观察组与对照组,各组均51例。对照组采取化疗(培美曲塞+奥沙利铂)治疗,观察组在对照组化疗治疗基础上结合参芪扶正方治疗,数据观察:近期治疗效果、化疗不良反应情况、肿瘤标志物水平变化、中医证候积分(吞咽困难、口干咽燥、自汗眩晕、五心烦热、少气懒言等)变化、患者生活质量上升率(Karnofsky,KPS)。结果对照组近期治疗总有效率为62.75%(32/51),观察组近期治疗总有效率为78.43%(40/51),后者更高(P<0.05);观察组化疗部分不良反应发生率低于对照组(P<0.05);治疗前,两组糖蛋白125(carbohydrate antigen125,CA125)及糖蛋白153(carbohydrate antigen153,CA153)、癌胚抗原(carcinoembryonic antigen,CEA)等肿瘤标志物水平、中医证候积分(吞咽困难、口干咽燥、自汗眩晕、五心烦热、少气懒言等)比较,P>0.05,治疗后两组CA125及CA153、CEA等肿瘤标志物水平、中医证候积分(吞咽困难、口干咽燥、自汗眩晕、五心烦热、少气懒言等)均下降,较对照组,观察组CA125及CA153、CEA等肿瘤标志物水平、中医证候积分(吞咽困难、口干咽燥、自汗眩晕、五心烦热、少气懒言等)均更低(P<0.05);观察组生活质量上升率(78.43%)显著高于对照组(58.82%)(P<0.05)。结论参芪扶正方结合化疗(培美曲塞+奥沙利铂)治疗晚期贲门癌临床效果显著,肿瘤得以抑制,症状缓解,化疗不良反应一定程度降低,安全性较高,且生活质量较好,值得应用。
Objective To investigate the clinical effect of Shenqi Fuzheng Prescription(参芪扶正方)combined with chemotherapy(pemetrexed+oxaliplatin)in the treatment of advanced cardiac cancer.Methods A total of 102 patients with advanced cardiac cancer(admitted from May 2019 to October 2021)were enrolled and divided into observation group and control group by random number table method,with 51 patients in each group.Patients in the control group were treated with chemotherapy(pemetrexed+oxaliplatin),and those in the observation group were treated with Shenqi Fuzheng Prescription on the basis of chemotherapy in the control group.Data observation:Recent treatment effect,chemotherapy side effects,changes in tumor marker levels,changes in TCM syndrome scores(dysphagia,dry mouth,dizziness due to spontaneous sweating,dysphoria in chest-palms-soles,lack of breath,laziness,etc),and the improvement rate of patients’quality of life(KPS)were compared.Results The total effective rate was 62.75%(32/51)in the control group and 78.43%(40/51)in the observation group,which was higher than that in the control group(P<0.05).The incidence of partial chemotherapy side effects in the observation group was lower than that in the control group(P<0.05).Before treatment,the levels of glycoprotein 125(CA125),glycoprotein 153(CA153),carcinoembryonic antigen(CEA)and other tumor markers,and TCM syndrome scores(dysphagia,dry mouth,dizziness due to spontaneous sweating,dysphoria in chest-palms-soles,lack of breath,laziness,etc)in two groups were not significant(P>0.05).After treatment,the levels of CA125,CA153,CEA and other tumor markers,as well as TCM syndrome scores(dysphagia,dry mouth,dizziness due to spontaneous sweating,dysphoria in chest-palms-soles,lack of breath,laziness,etc)in the two groups decreased.Compared with those of the control group,the levels of CA125,CA153,CEA and other tumor markers,TCM syndrome scores(dysphagia,dry mouth,dizziness due to spontaneous sweating,dysphoria in chest-palms-soles,lack of breath,laziness,etc)in the obs
作者
范韶玮
白英成
FAN Shaowei;BAI Yingcheng(The 971st Naval Hospital,Qingdao 266071,Shandong,China)
出处
《中华中医药学刊》
CAS
北大核心
2023年第1期222-225,共4页
Chinese Archives of Traditional Chinese Medicine
基金
山东省医药卫生科技发展计划项目(2018WS0726)。
关键词
晚期贲门癌
化疗
培美曲塞
奥沙利铂
参芪扶正方
近期疗效
化疗不良反应
advanced cardiac cancer
chemotherapy
pemetrexed
oxaliplatin
Shenqi Fuzheng Prescription(参芪扶正方)
short-term efficacy
Chemotherapeutic side effect
